We are a biotechnology company pioneering RNA-based therapeutics to address high unmet medical needs in cardiovascular, metabolic, rare liver, and rare kidney diseases. Our proprietary DARGER™ platform enables both gene upregulation and downregulation using novel antisense oligonucleotide (ASO) and small interfering RNA (siRNA) approaches.
Location: United States, California, San Diego
Investors 1
| Date | Name | Website |
| 11.11.2025 | New Allian... | nac-capita... |
Mentions in press and media 2
| Date | Title | Description |
| 09.04.2024 | Biotech startup Arnatar raises $50m Series A round to build China presence | Biotech startup Arnatar Therapeutics has secured $50 million in a Series A funding round to speed up the development of its drug pipeline, accelerate clinical trials, and build a presence in China. |
| - | Arnatar Therapeutics | “arnatar” |